L3VLUP
ProSign in

SUPN in the 13F filings

Supernus Pharmaceuticals Inc · CUSIP 868459108

Sector · Pharmaceuticals and biotechnologyTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Pharmaceutical preparations
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Quarter end
31 Dec 2024
the date the book describes
Filed
14 Feb 2025
latest of these filings; the earliest 13 Feb 2025
Managers listing it
3
at least, of 95 tracked, among listed positions
Comparable managers
94
filed both Q3 2024 and Q4 2024; 3 listed it in both
Shares listed
2,077,558
combined, among listed positions
Reported value
$75m
combined, at the quarter end

Among the 94 comparable managers: 2 buyers (opened or added shares) and 1 seller (trimmed or exited), at least, among listed positions. Their net change in shares was +123,255.

Managers listing SUPN in Q4 2024

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q3 2024, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

3 of 3 holders

ActionFiling
Renaissance Technologies LLC1,598,722$58m0.09%Trimmed-129,90013 Feb 2025 (the filing on sec.gov)
Woodline Partners LP423,828$15m0.10%Added+235,25714 Feb 2025 (the filing on sec.gov)
PDT Partners LLC55,008$2.0m0.18%Added+17,89814 Feb 2025 (the filing on sec.gov)

Largest increases and reductions, by shares

Q3 2024 to Q4 2024, among managers that listed it in both quarters or opened it.

Increases

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (0)

No new position among listed positions.

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
3 in Q3 2024 to 6 in Q2 2026

Tracked managers listing it, at least.

035810201620182020202220242026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
SUPN by quarter
QuarterHoldersReported valueBuyersSellers
Q2 20141$1.1mn.a.n.a.
Q1 20151$1.3mn.a.n.a.
Q2 20152$10mn.a.n.a.
Q3 20151$10mn.a.n.a.
Q4 20152$23mn.a.n.a.
Q1 20163$38mn.a.n.a.
Q2 20162$33mn.a.n.a.
Q3 20161$43mn.a.n.a.
Q4 20161$42mn.a.n.a.
Q1 20171$51mn.a.n.a.
Q2 20172$68mn.a.n.a.
Q3 20173$53mn.a.n.a.
Q4 20171$51mn.a.n.a.
Q1 20185$70mn.a.n.a.
Q2 20183$122mn.a.n.a.
Q3 20182$45mn.a.n.a.
Q4 20185$50mn.a.n.a.
Q1 20195$61mn.a.n.a.
Q2 20196$54mn.a.n.a.
Q3 20193$46mn.a.n.a.
Q4 20196$28mn.a.n.a.
Q1 20207$29mn.a.n.a.
Q2 20204$33mn.a.n.a.
Q3 20203$49mn.a.n.a.
Q4 20201$47mn.a.n.a.
Q1 20211$46mn.a.n.a.
Q2 20212$48mn.a.n.a.
Q3 20213$40mn.a.n.a.
Q4 20212$36mn.a.n.a.
Q1 20224$62mn.a.n.a.
Q2 20224$62mn.a.n.a.
Q3 20225$75mn.a.n.a.
Q4 20225$53mn.a.n.a.
Q1 20233$55mn.a.n.a.
Q2 20232$45mn.a.n.a.
Q3 20231$40mn.a.n.a.
Q4 20231$40m01
Q1 20243$91m21
Q2 20241$45m12
Q3 20243$61m30
Q4 20243$75m21
Q1 20253$54m12
Q2 20253$80m30
Q3 20256$244m51
Q4 20259$381m1714
Q1 20268$399m1715
Q2 20266$299m1516

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

SUPN and LLY →SUPN and JNJ →SUPN and VRTX →Choose a stock to compare with SUPN →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own SUPN, latest filings →Back to the 13F Explorer →